Holen Sie sich die Stockscreener-App
3.55
3.27%
-0.12
Handel nachbörslich:
3.58
0.03
+0.85%
Sana Biotechnology Inc Aktie (SANA) Neueste Nachrichten
Sana Biotechnology (NASDAQ:SANA): Can Cell Therapy Drive the Next Chapter? - Kalkine Media
ARCH venture funds disclose 15%+ Sana Biotechnology (SANA) ownership in updated filing - Stock Titan
Sana Biotechnology | SCHEDULE 13G/A: Others - Moomoo
Bank of America Issues Pessimistic Forecast for Sana Biotechnology (NASDAQ:SANA) Stock Price - marketbeat.com
Sana Biotechnology (NASDAQ:SANA) Shares Down 5.3%Should You Sell? - marketbeat.com
Sana Biotechnology, Inc. Stock 12‑Month Price Target Cut to $9.38, Implies 155% Upside - TradingView
BofA Securities Adjusts Sana Biotechnology Price Target to $6 From $7 - marketscreener.com
HC Wainwright Has Pessimistic Outlook of SANA Q3 Earnings - marketbeat.com
Sana Biotechnology: Insulin-Producing Cells Survive 14 Months Without Immunosuppression As Mayo Clinic Invests $25 Million - Pulse 2.0
Wedbush Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $7 - moomoo.com
Sana Biotechnology (SANA) Is Up 13.5% After Narrower Losses And Mayo Clinic Equity DealWhat's Changed - simplywall.st
SANA SWOT Analysis: Financial Challenges and Growth Potential Revealed in 10-Q Filing - GuruFocus
Sana Biotechnology | 10-Q: Quarterly report - moomoo.com
Sana Biotechnology non-GAAP EPS beats estimate; cash runway extends to mid-2027 - scanx.trade
Sana Biotechnology falls 5% despite beating earnings estimates By Investing.com - Investing.com India
Sana Biotechnology falls 5% despite beating earnings estimates - Investing.com
Sana Biotechnology Q2 adjusted loss narrows, beats estimates - Bitget
Sana Biotechnology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Sana Biotechnology (NASDAQ:SANA) Issues Earnings Results - marketbeat.com
Sana Biotechnology Q2 Adjusted Loss Narrows - marketscreener.com
Earnings Flash (SANA) Sana Biotechnology, Inc. Posts Q2 Adjusted Loss $0.13 per Share, vs. FactSet Est of $-0.12 - marketscreener.com
Sana Biotechnology (SANA) warns on going concern amid $110.8M loss - stocktitan.net
Sana: Q2 Earnings Snapshot - ktvb.com
BRIEF-Sana Biotechnology Q2 Adjusted EPS USD -0.13 Vs. IBES Estimate USD -0.15 - TradingView
Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates - Yahoo Finance
Sana Biotechnology faces earnings test as CAR-T program advances By Investing.com - Investing.com UK
Sana Biotechnology faces earnings test as CAR-T program advances - Investing.com
Sana Biotechnology Inc (SANA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Sana Biotechnology, Inc. (SANA) Stock Analysis: Exploring a Promising 151% Potential Upside - DirectorsTalk Interviews
Sana Biotechnology (SANA) Projected to Release Earnings on Monday - MarketBeat
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
Sana Biotechnology Inc (SANA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Sana Biotechnology Inc (SANA) Valuation: PE, PB & Fair Value Analysis - TradingKey
SANA|Sana Biotechnology Inc|Price:3.285|Chg%:+0.105 - TradingKey
Sana Biotechnology Inc (SANA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Sana Biotechnology Inc (SANA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Sana Biotechnology (NASDAQ:SANA) Stock Price Up 6.8%Should You Buy? - marketbeat.com
TradingKey - TradingKey
Sana Biotechnology Inc (SANA) Institutional Confidence - TradingKey
Sana Biotechnology: Promising Science, But Dilution Keeps The Rating A Hold (NASDAQ:SANA) - Seeking Alpha
Sana Biotechnology Inc (SANA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sana Biotechnology, Inc. Revenue Breakdown – NASDAQ:SANA - TradingView
SANA|Sana Biotechnology Inc|Price:3.190|Chg%:-0.020 - TradingKey
SANA|Sana Biotechnology Inc|Price:3.215|Chg%:+0.095 - TradingKey
Sana Biotechnology, Inc. (SANA) Stock Analysis: Exploring a 167% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
SANA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Sana Biotechnology: A $1 Billion Market Cap Built On A Pre-Phase 1 Foundation - Seeking Alpha
Sana Biotechnology (SANA) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Sana Biotechnology (NASDAQ:SANA) Rating Lowered to "Sell" at Wall Street Zen - marketbeat.com
Sana Biotechnology (SANA) Experiences Modest Decline as Stock Nears Support ZoneGolden Cross - dars.gov.et
Sana Biotechnology (SANA) Publishes 14 Month Diabetes Cell Therapy Results In NEJM - Yahoo Finance
Sana Biotechnology (SANA) Edges Lower Amid Biotech Sector Volatility; Key Support Levels in FocusTick Index - dars.gov.et
Sana Biotechnology - Nasdaq
Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 D - The Manila Times
Sana Biotechnology Announces Follow-On Publication in The - GlobeNewswire
Shareholders of Sana Biotechnology, Inc. Should Contact Levi & Ko - The National Law Review
Securities Lawsuit Alert: Sana Biotechnology, Inc. (SANA)Contact Levi & Korsinsky Before May 20, 2025 - The National Law Review
Sana Biotechnology (SANA) Is Up 18.1% After Removal From Key Russell Value IndexesWhat's Changed - simplywall.st
Sana Biotech heads to EASD with diabetes cell therapy update - Longevity.Technology
The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy - PR Newswire
Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Bishop Hans Edgar - Moomoo
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):